Literature DB >> 10411157

Leg ulcers and hydroxyurea: forty-one cases.

M E Sirieix1, C Debure, N Baudot, L Dubertret, M E Roux, P Morel, C Frances, S Loubeyres, C Beylot, D Lambert, P Humbert, O Gauthier, M Dandurand, B Guillot, L Vaillant, G Lorette, J M Bonnetblanc, C Lok, J P Denoeux.   

Abstract

BACKGROUND: Hydroxyurea is an antitumor agent used to treat chronic myeloproliferative disorders. Leg ulcerations have been reported in patients undergoing long-term hydroxyurea therapy for myeloproliferative diseases. To better define this dermatological adverse effect of hydroxyurea therapy and to try to understand the pathophysiological process of this disease, we collected medical information for such patients in a multicenter retrospective study. OBSERVATIONS: Forty-one patients (mean age, 67 years) developed leg ulcerations while undergoing hydroxyurea therapy (mean therapy duration, 5 years). The sex ratio was 1, and there was no underlying vascular disease. Hematologic abnormalities were identified. Complete recovery from the ulcerations occurred quickly after withdrawal of treatment in 33 (80%) of the cases.
CONCLUSIONS: This longest-reported series of patients confirms the role of hydroxyurea therapy in the onset of leg ulcerations. Healing or improvement requires cessation of treatment. Cutaneous atrophy and impaired wound healing may explain the relationship between hydroxyurea and leg ulcers. In addition, the megaloblastic erythrocytes resulting from the presence of hydroxyurea may circulate poorly through the capillary network. A prospective study in hematologic centers would be valuable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411157     DOI: 10.1001/archderm.135.7.818

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  21 in total

1.  [Painful symmetrical ankle ulcerations. A 73-year old patient with chronic myeloid leukemia].

Authors:  K Welt; S Ott; J M Weiss; K Scharffetter-Kochanek
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

2.  Hydroxyurea-induced ulcers on the leg.

Authors:  Joachim Dissemond; Andreas Körber
Journal:  CMAJ       Date:  2009-05-26       Impact factor: 8.262

Review 3.  Polycythemia Vera Management and Challenges in the Community Health Setting.

Authors:  Aaron T Gerds; Kim-Hien Dao
Journal:  Oncology       Date:  2017-01-18       Impact factor: 2.935

Review 4.  Vasculitic and autoimmune wounds.

Authors:  Victoria K Shanmugam; Divya Angra; Hamza Rahimi; Sean McNish
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2016-12-14

5.  A Hydroxyurea-induced Leg Ulcer.

Authors:  Seon-Wook Hwang; Soon-Kwon Hong; Sang-Hyun Kim; Jong-Keun Seo; Deborah Lee; Ho-Suk Sung
Journal:  Ann Dermatol       Date:  2009-02-28       Impact factor: 1.444

6.  Malleolar Ulceration Induced by Hydroxyurea Therapy for Chronic Eosinophila.

Authors:  Justin R Bryant; Peter Andrade; Raymond T Hajjar; Christopher R Lumley; Kongkrit Chaiyasate
Journal:  J Am Coll Clin Wound Spec       Date:  2017-01-05

Review 7.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 8.  [Ulcers following therapy with hydroxyurea. Three case reports and review of the literature].

Authors:  S Boneberger; R A Rupec; T Ruzicka
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

9.  Drug delivery of hydroxyurea to breast cancer using liposomes.

Authors:  Seyed Ebrahim Alavi; Maedeh Koohi Moftakhari Esfahani; Fatemeh Alavi; Fatemeh Movahedi; Azim Akbarzadeh
Journal:  Indian J Clin Biochem       Date:  2012-12-28

10.  Leg ulcers in sickle cell disease: current patterns and practices.

Authors:  Kara-Marie H Delaney; Karen C Axelrod; Ashley Buscetta; Kathryn L Hassell; Patricia E Adams-Graves; Catherine Seamon; Gregory J Kato; Caterina P Minniti
Journal:  Hemoglobin       Date:  2013-04-19       Impact factor: 0.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.